BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 17943965)

  • 1. Acute megakaryoblastic leukemia in Down syndrome.
    Hitzler JK
    Pediatr Blood Cancer; 2007 Dec; 49(7 Suppl):1066-9. PubMed ID: 17943965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts.
    Langebrake C; Creutzig U; Reinhardt D
    Klin Padiatr; 2005; 217(3):126-34. PubMed ID: 15858703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Origins of leukaemia in children with Down syndrome.
    Hitzler JK; Zipursky A
    Nat Rev Cancer; 2005 Jan; 5(1):11-20. PubMed ID: 15630411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder.
    Cushing T; Clericuzio CL; Wilson CS; Taub JW; Ge Y; Reichard KK; Winter SS
    J Pediatr; 2006 May; 148(5):687-9. PubMed ID: 16737888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transient leukemia in newborns with Down syndrome.
    Massey GV
    Pediatr Blood Cancer; 2005 Jan; 44(1):29-32. PubMed ID: 15558701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis.
    Roy A; Roberts I; Norton A; Vyas P
    Br J Haematol; 2009 Oct; 147(1):3-12. PubMed ID: 19594743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transient leukemia (transient myeloproliferative disorder, transient abnormal myelopoiesis) of Down syndrome.
    Brink DS
    Adv Anat Pathol; 2006 Sep; 13(5):256-62. PubMed ID: 16998319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down myeloid disorders: a paradigm for childhood preleukaemia and leukaemia and insights into normal megakaryopoiesis.
    Vyas P; Roberts I
    Early Hum Dev; 2006 Dec; 82(12):767-73. PubMed ID: 17064858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct clones are associated with the development of transient myeloproliferative disorder and acute megakaryocytic leukemia in a patient with Down syndrome.
    Kanegane H; Watanabe S; Nomura K; Xu G; Ito E; Miyawaki T
    Int J Hematol; 2007 Oct; 86(3):250-2. PubMed ID: 17988992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome.
    Wechsler J; Greene M; McDevitt MA; Anastasi J; Karp JE; Le Beau MM; Crispino JD
    Nat Genet; 2002 Sep; 32(1):148-52. PubMed ID: 12172547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GATA1 as a new target to detect minimal residual disease in both transient leukemia and megakaryoblastic leukemia of Down syndrome.
    Pine SR; Guo Q; Yin C; Jayabose S; Levendoglu-Tugal O; Ozkaynak MF; Sandoval C
    Leuk Res; 2005 Nov; 29(11):1353-6. PubMed ID: 15916804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome.
    Hitzler JK; Cheung J; Li Y; Scherer SW; Zipursky A
    Blood; 2003 Jun; 101(11):4301-4. PubMed ID: 12586620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome.
    Greene ME; Mundschau G; Wechsler J; McDevitt M; Gamis A; Karp J; Gurbuxani S; Arceci R; Crispino JD
    Blood Cells Mol Dis; 2003; 31(3):351-6. PubMed ID: 14636651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of acute megakaryoblastic leukemia from a minor clone in a Down syndrome patient with clinically overt transient myeloproliferative disorder.
    Xu G; Kato K; Toki T; Takahashi Y; Terui K; Ito E
    J Pediatr Hematol Oncol; 2006 Oct; 28(10):696-8. PubMed ID: 17023834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A rare case of GATA1 negative chemoresistant acute megakaryocytic leukemia in an 8-month-old infant with trisomy 21.
    Stepensky P; Brooks R; Waldman E; Revel-Vilk S; Izraeli S; Resnick I; Weintraub M
    Pediatr Blood Cancer; 2010 Jul; 54(7):1048-9. PubMed ID: 20108342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia.
    Ge Y; Stout ML; Tatman DA; Jensen TL; Buck S; Thomas RL; Ravindranath Y; Matherly LH; Taub JW
    J Natl Cancer Inst; 2005 Feb; 97(3):226-31. PubMed ID: 15687366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [GATA1-mutation associated leukemia in children with trisomy 21 mosaic].
    Reinhardt D; Reinhardt K; Neuhoff C; Sander A; Klusmann JH; Pekrun A; Sauerbrey A; von Stackelberg A; Rössig C; Creutzig U; Kolenova A
    Klin Padiatr; 2012 Apr; 224(3):153-5. PubMed ID: 22513796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chromosome 7 abnormalities in acute megakaryoblastic leukemia associated with Down syndrome.
    Kobayashi K; Usami I; Kubota M; Nishio T; Kakazu N
    Cancer Genet Cytogenet; 2005 Apr; 158(2):184-7. PubMed ID: 15796967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21.
    Rainis L; Bercovich D; Strehl S; Teigler-Schlegel A; Stark B; Trka J; Amariglio N; Biondi A; Muler I; Rechavi G; Kempski H; Haas OA; Izraeli S
    Blood; 2003 Aug; 102(3):981-6. PubMed ID: 12649131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct gene signatures of transient and acute megakaryoblastic leukemia in Down syndrome.
    Lightfoot J; Hitzler JK; Zipursky A; Albert M; Macgregor PF
    Leukemia; 2004 Oct; 18(10):1617-23. PubMed ID: 15343346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.